Vijayaganesh Kasinathan's Profile

B.Pharm, M.Pharm

Vijayaganesh Kasinathan

Vijayaganesh, has completed his M. Pharm from Periyar college of Pharmaceutical Sciences in Trichy. He has five years of overseas experience working in Muscat and Qatar, as a pharmacist. He looks ahead to explore possibilities of safe medicine usage in space travel. His hobbies include traveling, view more..

Written / Edited / Medically Reviewed

Alectinib May Be Drug Of Choice to Treat Non-Small-Cell Lung Cancer

Alectinib May Be Drug Of Choice to Treat Non-Small-Cell Lung Cancer

Alectinib, a next generation tyrosine kinase inhibitor found to improve the symptoms associated with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer than with the standard treatment of crizotinib.

Health In Focus
Breast Cancer Patients Can Reduce The Rate Of Associated Heart Disease

Breast Cancer Patients Can Reduce The Rate Of Associated Heart Disease

Breast cancer patients have the higher risk of getting the heart disease while undergoing cancer treatment which can be managed well by early screening and adequate treatment.

Health In Focus
Mefloquine May Be Effective in Preventing Malaria in Pregnant Women

Mefloquine May Be Effective in Preventing Malaria in Pregnant Women

Pregnant women who live in malaria transmission areas are more prone to the disease particularly if they are affected by HIV. The drug Mefloquine can help to prevent malaria in pregnancy.

Health In Focus
FDA Approves Abemaciclib to Treat Women With Certain Breast Cancers

FDA Approves Abemaciclib to Treat Women With Certain Breast Cancers

Abemaciclib was approved by FDA for treating postmenopausal women with certain types of breast cancer in combination with aromatase inhibitors in whom cancer has progressed despite the endocrine therapy.

Health In Focus
Probiotics may Prevent Clostridium Difficile-associated Diarrhea's Occurrence

Probiotics may Prevent Clostridium Difficile-associated Diarrhea's Occurrence

Probiotics were found to lessen the occurrence of Clostridium difficile-associated diarrhea (CDAD) in patients receiving antibiotics and a significant reduction in side effects when compared with a control group or placebo.

Health In Focus